Global Home Global Home  
 
 

News

Date Title and Summary Additional Formats
Toggle Summary Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data
Highest quarterly prescriptions filled in company's history
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Publication of Consensus Report Describing Celacyn's (Hypochlorous Acid) Impact on Post-Procedure Treatment and Scar Prevention
PETALUMA, Calif. , June 28, 2017 (GLOBE NEWSWIRE) -- A distinguished panel of U.S. dermatologists and plastic surgeons explored current literature to establish the value of hypochlorous acid (HOCl) as both a pre- and post-procedure regime aimed at prevention of infection, reduction of inflammation
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Two Singapore Approvals for Microcyn® (hypochlorous acid) for the Treatment of Atopic Dermatitis and Hypertrophic / Keloid Scars
PETALUMA, Calif. , June 20, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced
View HTML
Toggle Summary Sonoma Pharmaceuticals Reports Financial Results for Fourth Quarter and Fiscal Year 2017
Product revenue for fourth quarter up 60% and for fiscal year 2017 up 48%, compared to last year, driven by growth in U.S. dermatology sales Cash position of $17.5 million ; management believes the company is more than fully funded to achieve EBITDA breakeven                      Conference Call
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2017 Financial Results and Conference Call
PETALUMA, Calif. , June 02, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal year and fourth quarter 2017, ended March 31, 2017 , will be released after the U.S. markets close on June 5, 2017 .
View HTML
Toggle Summary Sonoma Pharmaceuticals Receives Two New United Arab Emirates Regulatory Approvals: Pediacyn® For Atopic Dermatitis And Epicyn® For Scar Management
PETALUMA, Calif., April 12, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced it
View HTML
Toggle Summary Blog Coverage Sonoma Pharmaceuticals Announced FDA Clearance For Loyon Skin Descaler
Upcoming AWS Coverage on Amphastar Pharmaceuticals Post-Earnings Results
View HTML
Toggle Summary Sonoma Pharmaceuticals Receives U.S. FDA Clearance of Loyon® Skin Descaler for Relief of Scaling Associated with Various Dermatoses
PETALUMA, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced it
View HTML
Toggle Summary Sonoma Pharmaceuticals Receives Final $1.5 Million Payment from Sale of Latin America Business to Invekra S.A.P.I. de C.V.
PETALUMA, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Results from Sebuderm™ Gel Study in Treatment of Seborrheic Dermatitis
Evaluation of SebuDerm (hypochlorous acid) Gel on Mild to Moderate Facial and Scalp Seborrheic Dermatitis Investigator Global Assessment (IGA) Scores Showed a 33% Improvement at Day 14 and a 52% Improvement at Day 28 Clinical Poster being Presented at the 13th Annual Maui Dermatology Conference on
View HTML